Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Neutral endopeptidase (NEP) is a cell surface enzyme that degrades active peptides.
• Basic fibroblast growth factor (FGF-2) is implicated in cancer progression and angiogenesis.
• DU145 prostate cancer cells are deficient in NEP, making them a model for studying NEP's effects.

Purpose of the Study:

• To investigate the impact of overexpressing NEP on prostate cancer cell tumorigenicity.
• To determine if NEP affects FGF-2 levels and angiogenesis in prostate cancer.
• To explore the therapeutic potential of NEP in prostate cancer treatment.

Main Methods:

• Lentiviral vectors were used to stably introduce wild-type NEP (L-NEP), inactive NEP mutant (L-NEPmu), or GFP (L-GFP) into DU145 cells.
• FGF-2 levels in cell culture supernatants were quantified.
• In vitro tubulogenesis assays were performed using conditioned media.
• Tumor xenografts were established and analyzed for size and vascularity.

Main Results:

• L-NEP expression significantly reduced FGF-2 levels by 80% compared to controls.
• Conditioned media from L-NEP cells showed reduced ability to induce endothelial cell tubulogenesis.
• Tumor xenografts from L-NEP cells were significantly smaller with decreased vascularity.
• Other angiogenic factors were not significantly altered.

Conclusions:

• Stable expression of NEP in DU145 prostate cancer cells inhibits tumorigenicity.
• NEP suppresses prostate cancer growth and angiogenesis, likely through proteolytic inactivation of FGF-2.
• NEP represents a potential therapeutic target for inhibiting prostate cancer progression.